IRAK3 and neoplasm: Using a range of carcinogen-induced or oncogene-driven murine tumor models, our data show that IRAK3 deficiency resulted in enhanced activation of myeloid cells in tumor tissues, which could improve the migratory and antigen-presentation capacity of the cells (26).